These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 28938491)
21. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice. Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636 [TBL] [Abstract][Full Text] [Related]
22. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168 [TBL] [Abstract][Full Text] [Related]
23. Fibroblast Growth Factor 2 High Molecular Weight Isoforms in Dentoalveolar Mineralization. Millington G; Joseph J; Xiao L; Vijaykumar A; Mina M; Hurley MM Calcif Tissue Int; 2022 Jan; 110(1):93-103. PubMed ID: 34245331 [TBL] [Abstract][Full Text] [Related]
24. Mineralized tissues in hypophosphatemic rickets. Robinson ME; AlQuorain H; Murshed M; Rauch F Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of bone density and microarchitecture in adult patients with X-linked hypophosphatemic rickets: A pilot longitudinal study. Funck-Brentano T; Vanjak A; Ostertag A; Nethander M; Fernandez S; Collet C; Hans D; van Rietbergen B; Cohen-Solal M Bone; 2024 Oct; 187():117179. PubMed ID: 38960298 [TBL] [Abstract][Full Text] [Related]
26. SPR4-peptide alters bone metabolism of normal and HYP mice. Zelenchuk LV; Hedge AM; Rowe PS Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577 [TBL] [Abstract][Full Text] [Related]
27. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898 [TBL] [Abstract][Full Text] [Related]
28. Knockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasis. Homer-Bouthiette C; Doetschman T; Xiao L; Hurley MM J Biol Chem; 2014 Dec; 289(52):36303-14. PubMed ID: 25389287 [TBL] [Abstract][Full Text] [Related]
29. Pathogenic role of Fgf23 in Dmp1-null mice. Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986 [TBL] [Abstract][Full Text] [Related]
30. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065 [TBL] [Abstract][Full Text] [Related]
31. Osteocytes and the pathogenesis of hypophosphatemic rickets. Yamazaki M; Michigami T Front Endocrinol (Lausanne); 2022; 13():1005189. PubMed ID: 36246908 [TBL] [Abstract][Full Text] [Related]
32. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309 [TBL] [Abstract][Full Text] [Related]
33. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse. Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089 [TBL] [Abstract][Full Text] [Related]
34. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice. Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD Bone; 2022 Jan; 154():116201. PubMed ID: 34537437 [TBL] [Abstract][Full Text] [Related]
35. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Brownstein CA; Zhang J; Stillman A; Ellis B; Troiano N; Adams DJ; Gundberg CM; Lifton RP; Carpenter TO Endocrinology; 2010 Feb; 151(2):492-501. PubMed ID: 19952276 [TBL] [Abstract][Full Text] [Related]
36. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Suvannasankha A; Tompkins DR; Edwards DF; Petyaykina KV; Crean CD; Fournier PG; Parker JM; Sandusky GE; Ichikawa S; Imel EA; Chirgwin JM Oncotarget; 2015 Aug; 6(23):19647-60. PubMed ID: 25944690 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of bone mineral density and microarchitectural parameters by DXA and HR-pQCT in 37 children and adults with X-linked hypophosphatemic rickets. Colares Neto GP; Pereira RM; Alvarenga JC; Takayama L; Funari MF; Martin RM Osteoporos Int; 2017 May; 28(5):1685-1692. PubMed ID: 28194480 [TBL] [Abstract][Full Text] [Related]
38. Skeletal inflammation and attenuation of Wnt signaling, Wnt ligand expression, and bone formation in atherosclerotic ApoE-null mice. Liu Y; Almeida M; Weinstein RS; O'Brien CA; Manolagas SC; Jilka RL Am J Physiol Endocrinol Metab; 2016 May; 310(9):E762-73. PubMed ID: 26956187 [TBL] [Abstract][Full Text] [Related]
39. Osteoblast-Specific Overexpression of Human WNT16 Increases Both Cortical and Trabecular Bone Mass and Structure in Mice. Alam I; Alkhouli M; Gerard-O'Riley RL; Wright WB; Acton D; Gray AK; Patel B; Reilly AM; Lim KE; Robling AG; Econs MJ Endocrinology; 2016 Feb; 157(2):722-36. PubMed ID: 26584014 [TBL] [Abstract][Full Text] [Related]
40. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]